 cisplatin first-lin chemotherapi metastat breast carcinoma prospect trial italian oncolog group clinic research prospect random studi first-lin treatment combin cisplatin standard cyclophosphamid methotrex fluorouracil cmf combin patient complet remiss assess patient cmf assess patient PE complet partial remiss rate cmf PE time progress median week durat respons week surviv week differ hematolog toxic PE gastrointestin side effect frequent treatment studi PE combin effect front-lin chemotherapi respons rate trend superior cmf borderlin signific due lack surviv advantag toxic combin routin clinic use high level activ account research